---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-035634"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:12:23.165984+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion raises ~$56.7M in registered direct offering; amends warrants to lower exercise price

## Summary
- Gross proceeds of ~$56.7M from sale of 33,170,747 shares (or equivalents) and warrants at $1.675 combined.
- Net proceeds expected ~$51.3M after placement agent fees and expenses.
- Short-term warrants exercisable at $1.55/share for 3.5 years; pre-funded warrants also offered.
- Amended 9,024,212 existing warrants from $9.00 to $1.55 exercise price for $0.125 per amended warrant.

## SEC filing metadata
- accession: 0001104659-23-035634
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/0001104659-23-035634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/tm2310183d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-035634
- JSON: https://secwatch.observer/filing/0001104659-23-035634.json
- Plain text: https://secwatch.observer/filing/0001104659-23-035634.txt

## Key facts
- Material Agreements
  Esperion Therapeutics, Inc. entered into Securities Purchase Agreement with certain purchasers named therein (effective 2023-03-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers named therein
  - Effective: 2023-03-19
  source text: On March 19, 2023, Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers named therein (the “Purchasers”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/0001104659-23-035634-index.htm
- Material Agreements
  Esperion Therapeutics, Inc. amended Warrant Amendment Agreements valued at approximately $1.13 million (effective 2023-12-07).
  - Action: amendment
  - Value: approximately $1.13 million
  - Effective: 2023-12-07
  source text: In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the “Warrant Amendment Agreements”), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/0001104659-23-035634-index.htm
- Material Agreements
  Esperion Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-03-16).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2023-03-16
  source text: Pursuant to a letter agreement, dated March 16, 2023 (the “Engagement Letter”), the Company engaged H.C. Wainwright & Co., LLC as its exclusive placement agent (the “Placement Agent”) in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/0001104659-23-035634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.